Novartis AG
Method of treating transplant rejection with silent Fc variants of anti-CD40 antibodies

Abstract:

The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.